GPT and neutropenia: A combination of olaparib 100 mg BID (capsule formulation; intermittent dosing on days 1–14) with gemcitabine 600 mg/m2 was administered i.v. on days 1, 8, and 15 every 4 weeks to 66 advanced solid tumors patients in a randomized dose-expansion trial; according to adverse event (increased alanine aminotransferase levels, neutropenia, and febrile neutropenia) observation, this regimen had an acceptable tolerability profile, and this dose combination could be used in further studies [111].